We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

EU Rejects Cymbalta For Fibromyalgia Treatment

Law360 (October 24, 2008, 12:00 AM EDT) -- In a blow to Eli Lilly & Co., the European Union's drug-regulating body has recommended against allowing the pharmaceutical giant to market Cymbalta as a fibromyalgia treatment after finding that the benefits of the drug – which is already approved in Europe for depression and anxiety – in the treatment of the disease do not outweigh its risks.

The European Medicines Agency's Committee for Medicinal Products for Human Use said Thursday it had adopted a negative opinion recommending the refusal of a change to the marketing...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.